BYNUCMA
LIVE

Serial Number

97896516

Owner

Bristol-Myers Squibb Company

Attorney

Marilyn F. Kelly

Filing Date

Apr 19, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BYNUCMA Trademark

Serial Number: 97896516

BYNUCMA is a trademark filed by Bristol-Myers Squibb Company on April 19, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

April 19, 2023

Registration Date

Not Registered

Published for Opposition

December 19, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 14, 2026 EXRA
SOU EXTENSION 4 GRANTED
Feb 4, 2026 EX4G
SOU EXTENSION 4 FILED
Feb 4, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 4, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 31, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jul 30, 2025 EX3G
SOU EXTENSION 3 FILED
Jul 30, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 30, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jan 27, 2025 EX2G
SOU EXTENSION 2 FILED
Jan 27, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 27, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 25, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jul 25, 2024 EX1G
SOU EXTENSION 1 FILED
Jul 25, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 25, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 13, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 19, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 19, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 29, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 9, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 8, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 7, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 7, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 10, 2023 GNRN
NON-FINAL ACTION E-MAILED
Aug 10, 2023 GNRT
NON-FINAL ACTION WRITTEN
Aug 10, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 9, 2023 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 15, 2023 NWOS
NEW APPLICATION ENTERED
Apr 22, 2023 NWAP